NanoLogix, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NNLX research report →
About the company
NanoLogix, Inc. , a biotechnology firm, specializes in developing and providing rapid diagnostic and live cell test kits. These kits are designed to accurately detect viable bacteria and a wide array of other microorganisms.
- CEO
- Bret T. Barnhizer
- IPO
- 2009
- Employees
- 7
- HQ
- Hubbard, OH, US
Price Chart
- Market Cap
- $11.96K
- P/E
- -0.01
- P/S
- 0.34
- P/B
- 0.02
- EV/EBITDA
- -0.09
- Div Yield
- 0.00%
- Gross Margin
- -1994.62%
- Op Margin
- -3646.21%
- Net Margin
- -3631.21%
- ROE
- -172.49%
- ROIC
- -182.60%
- Revenue
- $35.60K · -59.70%
- Net Income
- $-1,292,639 · 25.99%
- EPS
- $-0.01 · 29.17%
- Op Income
- $-1,297,979
- FCF YoY
- 39.57%
- 52W High
- $0.04
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -34.75
- Avg Volume
- 394
Get TickerSpark's AI analysis on NNLX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our NNLX coverage
Recent articles, reports, and earnings notes.
No research on NNLX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NNLX report →Similar companies
Peers in the same neighborhood.